 DURHAM, N.C., Dec. 14, 2020 GLOBE NEWSWIRE -- Precision BioSciences, Inc. Nasdaq: DTIL a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform, today announced that Abid Ansari, Chief Financial Officer, notified the Company that he will be leaving the organization after nearly five years to pursue a new career opportunity. Abid will continue with Precision through the end of 2020 to ensure a smooth transition. Alex Kelly, the Companys Chief Corporate Affairs Officer, will serve as the Companys Interim Chief Financial Officer with Shane Barton, the Companys Vice President and Corporate Controller, serving as interim principal accounting officer, reporting directly to Alex. 